Subscribe to RSS
DOI: 10.1055/a-2474-5644
Roles of ROCK/Myosin Pathway in Macrothrombocytopenia in Bernard–Soulier Syndrome
Authors
Funding This research was supported by the Thailand Science Research and Innovation Fund (Fundamental Fund), Chulalongkorn University. P.M. was supported by Ratchadapisek Somphot Fund for Postdoctoral Fellowship, Chulalongkorn University.

Abstract
Background
Megakaryocytes (MK) from Bernard–Soulier syndrome (BSS) induced pluripotent stem cells (iPSCs) yielded reduced numbers but increased sizes of platelets. The molecular mechanisms remain unclear. This study aims to determine roles of signaling molecules involved in this process.
Material and Methods
Wild-type (WT) iPSCs and iPSCs from BSS patients with GP1BA (BSS-A) or GP1BB (BSS-B) mutations were differentiated into MKs and platelets with or without myosin II inhibitor (blebbistatin), ROCK inhibitor (Y27632), and procaspase-3 activator (PAC-1). Proplatelet and platelet numbers and sizes were characterized. The iPSC lines containing tubulin-green fluorescent protein (GFP) reporters were constructed to observe proplatelet formation under time-lapse microscopy.
Result
BSS-derived MKs (BSS-MKs) yielded fewer but larger platelets compared with the WT. In the presence of blebbistatin, ROCK inhibitor, or PAC-1, WT, BSS-A, and BSS-B MKs could generate more platelets with decreased sizes, but PAC-1 caused CD42 loss on WT platelets. The proportions of proplatelet formation from MKs carrying tubulin-GFP were not different between WT and BSS-MKs, as well as among inhibitors. Notably, initially thick cytoplasmic processes were transformed into thin branching proplatelets over the observation time. The proplatelet shafts of BSS-MK became thinner in the presence of blebbistatin or ROCK inhibitor, but not of PAC-1, which displayed uneven F-actin distribution.
Conclusion
Inhibition of the ROCK/myosin pathway, downstream of GpIb, could restore normal morphology of proplatelets in BSS-MKs. Procaspase-3 activation could increase platelet yields, but with abnormal proplatelet and platelet structures. Our model can be used for therapeutic drug screening and a disease model for platelet production in the future.
Keywords
megakaryocytes - Bernard–Soulier syndrome - platelet formation - induced pluripotent stem cellAuthors' Contribution
P.M. designed the overall research, performed the experiments, analyzed data, interpreted and discussed the results, and wrote the manuscript; P.I. and N.L. performed the experiments and analyzed data; N.U. interpreted and discussed the results; N.I. designed the overall research, interpreted, and discussed the results; P.R. designed the overall research, analyzed data, interpreted and discussed the results, and wrote the manuscript. All the authors reviewed and approved the manuscript.
Publication History
Received: 10 September 2024
Accepted: 17 November 2024
Article published online:
18 December 2024
© 2024. Thieme. All rights reserved.
Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
-
References
- 1 Figueiredo C, Blaszczyk R. Genetically engineered blood pharming: generation of HLA-universal platelets derived from CD34+ progenitor cells. J Stem Cells 2014; 9 (03) 149-161
- 2 Suzuki D, Flahou C, Yoshikawa N. et al. iPSC-derived platelets depleted of HLA class I are inert to anti-HLA class I and natural killer cell immunity. Stem Cell Reports 2020; 14 (01) 49-59
- 3 Norbnop P, Ingrungruanglert P, Israsena N, Suphapeetiporn K, Shotelersuk V. Generation and characterization of HLA-universal platelets derived from induced pluripotent stem cells. Sci Rep 2020; 10 (01) 8472
- 4 Mekchay P, Ingrungruanglert P, Suphapeetiporn K. et al. Study of Bernard-Soulier syndrome megakaryocytes and platelets using patient-derived induced pluripotent stem cells. Thromb Haemost 2019; 119 (09) 1461-1470
- 5 Pawinwongchai J, Mekchay P, Nilsri N, Israsena N, Rojnuckarin P. Regulation of platelet numbers and sizes by signaling pathways. Platelets 2021; 32 (08) 1073-1083
- 6 Sugimoto N, Kanda J, Nakamura S. et al. iPLAT1: the first-in-human clinical trial of iPSC-derived platelets as a phase 1 autologous transfusion study. Blood 2022; 140 (22) 2398-2402
- 7 Vainchenker W, Arkoun B, Basso-Valentina F, Lordier L, Debili N, Raslova H. Role of Rho-GTPases in megakaryopoiesis. Small GTPases 2021; 12 (5-6): 399-415
- 8 Ghalloussi D, Dhenge A, Bergmeier W. New insights into cytoskeletal remodeling during platelet production. J Thromb Haemost 2019; 17 (09) 1430-1439
- 9 Junt T, Schulze H, Chen Z. et al. Dynamic visualization of thrombopoiesis within bone marrow. Science 2007; 317 (5845) 1767-1770
- 10 Machlus KR, Italiano Jr JE. The incredible journey: from megakaryocyte development to platelet formation. J Cell Biol 2013; 201 (06) 785-796
- 11 Kowata S, Isogai S, Murai K. et al. Platelet demand modulates the type of intravascular protrusion of megakaryocytes in bone marrow. Thromb Haemost 2014; 112 (04) 743-756
- 12 Brown E, Carlin LM, Nerlov C, Lo Celso C, Poole AW. Multiple membrane extrusion sites drive megakaryocyte migration into bone marrow blood vessels. Life Sci Alliance 2018; 1 (02) e201800061
- 13 Nishimura S, Nagasaki M, Kunishima S. et al. IL-1α induces thrombopoiesis through megakaryocyte rupture in response to acute platelet needs. J Cell Biol 2015; 209 (03) 453-466
- 14 Potts KS, Farley A, Dawson CA. et al. Membrane budding is a major mechanism of in vivo platelet biogenesis. J Exp Med 2020; 217 (09) e20191206
- 15 Liu H, Ishikawa-Ankerhold H, Winterhalter J. et al. Multiphoton in vivo microscopy of embryonic thrombopoiesis reveals the generation of platelets through budding. Cells 2023; 12 (19) 2411
- 16 Carminita E, Becker IC, Italiano JE. What it takes to be a platelet: evolving concepts in platelet production. Circ Res 2024; 135 (04) 540-549
- 17 Takayama N, Eto K. In vitro generation of megakaryocytes and platelets from human embryonic stem cells and induced pluripotent stem cells. Methods Mol Biol 2012; 788: 205-217
- 18 Kovács M, Tóth J, Hetényi C, Málnási-Csizmadia A, Sellers JR. Mechanism of blebbistatin inhibition of myosin II. J Biol Chem 2004; 279 (34) 35557-35563
- 19 Bachtler N, Torres S, Ortiz C. et al. The non-selective Rho-kinase inhibitors Y-27632 and Y-33075 decrease contraction but increase migration in murine and human hepatic stellate cells. PLoS One 2023; 18 (01) e0270288
- 20 Shao J, Welch WJ, Diamond MI. ROCK and PRK-2 mediate the inhibitory effect of Y-27632 on polyglutamine aggregation. FEBS Lett 2008; 582 (12) 1637-1642
- 21 Li F, Wei A, Bu L. et al. Procaspase-3-activating compound 1 stabilizes hypoxia-inducible factor 1α and induces DNA damage by sequestering ferrous iron. Cell Death Dis 2018; 9 (10) 1025
- 22 Spinler KR, Shin JW, Lambert MP, Discher DE. Myosin-II repression favors pre/proplatelets but shear activation generates platelets and fails in macrothrombocytopenia. Blood 2015; 125 (03) 525-533
- 23 Chang Y, Auradé F, Larbret F. et al. Proplatelet formation is regulated by the Rho/ROCK pathway. Blood 2007; 109 (10) 4229-4236
- 24 Avanzi MP, Goldberg F, Davila J, Langhi D, Chiattone C, Mitchell WB. Rho kinase inhibition drives megakaryocyte polyploidization and proplatelet formation through MYC and NFE2 downregulation. Br J Haematol 2014; 164 (06) 867-876
- 25 Roberts B, Haupt A, Tucker A. et al. Systematic gene tagging using CRISPR/Cas9 in human stem cells to illuminate cell organization. Mol Biol Cell 2017; 28 (21) 2854-2874
- 26 Dütting S, Gaits-Iacovoni F, Stegner D. et al. A Cdc42/RhoA regulatory circuit downstream of glycoprotein Ib guides transendothelial platelet biogenesis. Nat Commun 2017; 8: 15838
- 27 Pleines I, Hagedorn I, Gupta S. et al. Megakaryocyte-specific RhoA deficiency causes macrothrombocytopenia and defective platelet activation in hemostasis and thrombosis. Blood 2012; 119 (04) 1054-1063
- 28 Eckly A, Strassel C, Freund M. et al. Abnormal megakaryocyte morphology and proplatelet formation in mice with megakaryocyte-restricted MYH9 inactivation. Blood 2009; 113 (14) 3182-3189
- 29 Jarocha D, Vo KK, Lyde RB, Hayes V, Camire RM, Poncz M. Enhancing functional platelet release in vivo from in vitro-grown megakaryocytes using small molecule inhibitors. Blood Adv 2018; 2 (06) 597-606
- 30 Chen Y, Boukour S, Milloud R. et al. The abnormal proplatelet formation in MYH9-related macrothrombocytopenia results from an increased actomyosin contractility and is rescued by myosin IIA inhibition. J Thromb Haemost 2013; 11 (12) 2163-2175
- 31 Pal K, Nowak R, Billington N. et al. Megakaryocyte migration defects due to nonmuscle myosin IIA mutations underlie thrombocytopenia in MYH9-related disease. Blood 2020; 135 (21) 1887-1898
- 32 Pasapera AM, Schneider IC, Rericha E, Schlaepfer DD, Waterman CM. Myosin II activity regulates vinculin recruitment to focal adhesions through FAK-mediated paxillin phosphorylation. J Cell Biol 2010; 188 (06) 877-890
- 33 Shutova MS, Svitkina TM. Common and specific functions of nonmuscle myosin II paralogs in cells. Biochemistry (Mosc) 2018; 83 (12) 1459-1468
- 34 Charras GT, Yarrow JC, Horton MA, Mahadevan L, Mitchison TJ. Non-equilibration of hydrostatic pressure in blebbing cells. Nature 2005; 435 (7040) 365-369
- 35 Cheung A, Dantzig JA, Hollingworth S. et al. A small-molecule inhibitor of skeletal muscle myosin II. Nat Cell Biol 2002; 4 (01) 83-88
- 36 De Botton S, Sabri S, Daugas E. et al. Platelet formation is the consequence of caspase activation within megakaryocytes. Blood 2002; 100 (04) 1310-1317
- 37 Avanzi MP, Izak M, Oluwadara OE, Mitchell WB. Actin inhibition increases megakaryocyte proplatelet formation through an apoptosis-dependent mechanism. PLoS One 2015; 10 (04) e0125057
- 38 Morishima N, Nakanishi K. Proplatelet formation in megakaryocytes is associated with endoplasmic reticulum stress. Genes Cells 2016; 21 (07) 798-806
- 39 Bergmeier W, Piffath CL, Cheng G. et al. Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates GPIbalpha shedding from platelets in vitro and in vivo. Circ Res 2004; 95 (07) 677-683
- 40 Gardiner EE, Karunakaran D, Shen Y, Arthur JF, Andrews RK, Berndt MC. Controlled shedding of platelet glycoprotein (GP)VI and GPIb-IX-V by ADAM family metalloproteinases. J Thromb Haemost 2007; 5 (07) 1530-1537
- 41 Wang Z, Shi Q, Li S, Du J, Liu J, Dai K. Hyperthermia induces platelet apoptosis and glycoprotein Ibalpha ectodomain shedding. Platelets 2010; 21 (03) 229-237
- 42 Schoenwaelder SM, Jarman KE, Gardiner EE. et al. Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets. Blood 2011; 118 (06) 1663-1674
- 43 Wang Z, Cai F, Hu L, Lu Y. The role of mitochondrial permeability transition pore in regulating the shedding of the platelet GPIbα ectodomain. Platelets 2014; 25 (05) 373-381
- 44 Clarke MC, Savill J, Jones DB, Noble BS, Brown SB. Compartmentalized megakaryocyte death generates functional platelets committed to caspase-independent death. J Cell Biol 2003; 160 (04) 577-587